Overview

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Status:
Terminated

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

Summary

Patients with advanced GIST are treated with imatinib. This study seeks to look at a new therapeutic agent at the time of tumor progression following treatment with 600-800 mg daily of imatinib. The study is looking to see if Nilotinib (tasigna) alone or in combination with imatinib (gleevec) is more effective at controlling disease.

Phase:

Phase 2

Details

Lead Sponsor:

Fox Chase Cancer Center

Collaborator:

Novartis

Treatments:

Imatinib Mesylate